662 related articles for article (PubMed ID: 32366291)
41. Effect of pirfenidone in patients with more advanced idiopathic pulmonary fibrosis.
Costabel U; Albera C; Glassberg MK; Lancaster LH; Wuyts WA; Petzinger U; Gilberg F; Kirchgaessler KU; Noble PW
Respir Res; 2019 Mar; 20(1):55. PubMed ID: 30866942
[TBL] [Abstract][Full Text] [Related]
42. Pirfenidone Reduces Respiratory-related Hospitalizations in Idiopathic Pulmonary Fibrosis.
Ley B; Swigris J; Day BM; Stauffer JL; Raimundo K; Chou W; Collard HR
Am J Respir Crit Care Med; 2017 Sep; 196(6):756-761. PubMed ID: 28471697
[TBL] [Abstract][Full Text] [Related]
43. The effects and safety of pirfenidone in the treatment of idiopathic pulmonary fibrosis: a meta-analysis and systematic review.
Zang C; Zheng Y; Wang Y; Li L
Eur J Med Res; 2021 Oct; 26(1):129. PubMed ID: 34717762
[TBL] [Abstract][Full Text] [Related]
44. Predictive factors for the long-term use of pirfenidone in patients with fibrosing interstitial lung disease.
Katano T; Sekine A; Ikeda S; Yamakawa H; Misumi T; Okabayashi H; Okuda R; Kitamura H; Baba T; Komatsu S; Hagiwara E; Ogura T
Respir Investig; 2021 Jul; 59(4):414-420. PubMed ID: 33618993
[TBL] [Abstract][Full Text] [Related]
45. Pirfenidone for the treatment of idiopathic pulmonary fibrosis.
Poletti V; Ravaglia C; Tomassetti S
Expert Rev Respir Med; 2014 Oct; 8(5):539-45. PubMed ID: 25113033
[TBL] [Abstract][Full Text] [Related]
46. Pirfenidone and Nintedanib in idiopathic pulmonary fibrosis: Real-life experience in an Italian referral centre.
Bargagli E; Piccioli C; Rosi E; Torricelli E; Turi L; Piccioli E; Pistolesi M; Ferrari K; Voltolini L
Pulmonology; 2019; 25(3):149-153. PubMed ID: 30236523
[TBL] [Abstract][Full Text] [Related]
47. Pirfenidone for the treatment of idiopathic pulmonary fibrosis.
Xaubet A; Serrano-Mollar A; Ancochea J
Expert Opin Pharmacother; 2014 Feb; 15(2):275-81. PubMed ID: 24308635
[TBL] [Abstract][Full Text] [Related]
48. Efficacy of pirfenidone and disease severity of idiopathic pulmonary fibrosis: Extended analysis of phase III trial in Japan.
Taguchi Y; Ebina M; Hashimoto S; Ogura T; Azuma A; Taniguchi H; Kondoh Y; Suga M; Takahashi H; Nakata K; Sugiyama Y; Kudoh S; Nukiwa T;
Respir Investig; 2015 Nov; 53(6):279-87. PubMed ID: 26521105
[TBL] [Abstract][Full Text] [Related]
49. Adherence, Persistence, and Effectiveness in Real Life. Multicenter Long-Term Study on the Use of Pirfenidone and Nintedanib in the Treatment of Idiopathic Pulmonary Fibrosis.
Santoleri F; Auriemma L; Spacone A; Marinari S; Esposito F; De Vita F; Petragnani G; Di Fabio C; Di Fabio L; Costantini A
J Pharm Pract; 2022 Dec; 35(6):853-858. PubMed ID: 33878986
[TBL] [Abstract][Full Text] [Related]
50. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King TE; Bradford WZ; Castro-Bernardini S; Fagan EA; Glaspole I; Glassberg MK; Gorina E; Hopkins PM; Kardatzke D; Lancaster L; Lederer DJ; Nathan SD; Pereira CA; Sahn SA; Sussman R; Swigris JJ; Noble PW;
N Engl J Med; 2014 May; 370(22):2083-92. PubMed ID: 24836312
[TBL] [Abstract][Full Text] [Related]
51. Pirfenidone treatment of idiopathic pulmonary fibrosis.
Azuma A
Ther Adv Respir Dis; 2012 Apr; 6(2):107-14. PubMed ID: 22333982
[TBL] [Abstract][Full Text] [Related]
52. Pirfenidone in idiopathic pulmonary fibrosis.
Maher TM
Drugs Today (Barc); 2010 Jul; 46(7):473-82. PubMed ID: 20683502
[TBL] [Abstract][Full Text] [Related]
53. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.
Noble PW; Albera C; Bradford WZ; Costabel U; Glassberg MK; Kardatzke D; King TE; Lancaster L; Sahn SA; Szwarcberg J; Valeyre D; du Bois RM;
Lancet; 2011 May; 377(9779):1760-9. PubMed ID: 21571362
[TBL] [Abstract][Full Text] [Related]
54. Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.
Nathan SD; Albera C; Bradford WZ; Costabel U; du Bois RM; Fagan EA; Fishman RS; Glaspole I; Glassberg MK; Glasscock KF; King TE; Lancaster L; Lederer DJ; Lin Z; Pereira CA; Swigris JJ; Valeyre D; Noble PW; Wells AU
Thorax; 2016 May; 71(5):429-35. PubMed ID: 26968970
[TBL] [Abstract][Full Text] [Related]
55. Sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: A Phase IIb, randomised, double-blind, placebo-controlled study - Rationale and study design.
Behr J; Nathan SD; Harari S; Wuyts W; Kirchgaessler KU; Bengus M; Gilberg F; Wells AU
Respir Med; 2018 May; 138():13-20. PubMed ID: 29724385
[TBL] [Abstract][Full Text] [Related]
56. An Open-Label Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (RECAP).
Costabel U; Albera C; Lancaster LH; Lin CY; Hormel P; Hulter HN; Noble PW
Respiration; 2017; 94(5):408-415. PubMed ID: 28898890
[TBL] [Abstract][Full Text] [Related]
57. Pretreatment rate of decay in forced vital capacity predicts long-term response to pirfenidone in patients with idiopathic pulmonary fibrosis.
Biondini D; Balestro E; Lacedonia D; Cerri S; Milaneschi R; Luppi F; Cocconcelli E; Bazzan E; Clini E; Foschino Barbaro MP; Gregori D; Cosio MG; Saetta M; Spagnolo P
Sci Rep; 2018 Apr; 8(1):5961. PubMed ID: 29654244
[TBL] [Abstract][Full Text] [Related]
58. Clinical course of IPF in Italian patients during 12 months of observation: results from the FIBRONET observational study.
Poletti V; Vancheri C; Albera C; Harari S; Pesci A; Metella RR; Campolo B; Crespi G; Rizzoli S;
Respir Res; 2021 Feb; 22(1):66. PubMed ID: 33627105
[TBL] [Abstract][Full Text] [Related]
59. Real-Life Experience with Pirfenidone in Idiopathic Pulmonary Fibrosis in Argentina. A Retrospective Multicenter Study.
Caro FM; Alberti ML; Campins F; Enghelmayer JI; Fernández ME; Lancellotti D; Papucci T; Sebastiani JA; Paulin F
Arch Bronconeumol (Engl Ed); 2019 Feb; 55(2):75-80. PubMed ID: 30049557
[TBL] [Abstract][Full Text] [Related]
60. Effectiveness of pirfenidone in idiopathic pulmonary fibrosis according to the autoantibody status: a retrospective cohort study.
Song MJ; Lee SH; Jung JY; Kang YA; Park MS; Kim YS; Chang J; Kim SY
BMC Pulm Med; 2021 May; 21(1):145. PubMed ID: 33941141
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
